# A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT07123454** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 91 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** AZD4512

## Key facts

- **NCT ID:** NCT07123454
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-24
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123454, "A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT07123454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*